Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says
Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.
You may also be interested in...
The agency says human drug review costs were less than $1 billion in fiscal year 2013, the first time that’s happened since FY 2010.
Agency advocates may face stronger headwinds in their efforts to boost FDA funding after presidential budget request comes in nearly flat.
Industry avoided application supplement fees by using CBE submissions instead, forcing FDA to change its estimates and sending generic drug user fees higher.